- SK pharmteco and LOTTE BIOLOGICS have signed a Letter of Intent to collaborate on antibody-drug conjugate (ADC) development and manufacturing.
- The partnership aims to establish an integrated CDMO service platform covering the full ADC production chain.
SK pharmteco and LOTTE BIOLOGICS have signed a Letter of Intent (LOI) to form a strategic collaboration focused on strengthening their presence in the global antibody-drug conjugate (ADC) market.
The agreement will see both companies jointly explore offering one-stop CDMO services, combining their technical expertise to provide differentiated ADC solutions from development through to commercial-scale manufacturing.
Under the collaboration, LOTTE BIOLOGICS will leverage its cGMP manufacturing capabilities and global quality standards at its Syracuse Bio Campus in the United States, providing bioconjugation and drug substance manufacturing services. SK pharmteco will take responsibility for linker–payload development and manufacturing within the chemical synthesis segment, complementing LOTTE BIOLOGICS’ biologics expertise.
The companies intend to build a fully integrated CDMO platform that bridges development and manufacturing, offering customised solutions and reducing supply chain complexity for clients. They will also pursue joint marketing and client engagement to expand their reach across global markets.
“This strategic partnership will supercharge the development of next-generation therapeutics, positioning both companies to deliver significantly greater value and accelerate the delivery of innovative new medicines to patients around the world.”
Joerg Ahlgrimm, CEO of SK pharmteco
“This collaboration marks a meaningful milestone, as two leading Korean biopharma companies join forces on the global stage. By combining our strengths in advanced modalities such as ADCs, we will reinforce Korea’s biopharmaceutical leadership and accelerate our growth in the global market.”
James Park, CEO of LOTTE BIOLOGICS
